Biogened S.A (BGD) fair value: what the stock is really worth
As of Nov 3, 2026: fair value (intrinsic value) of Biogened S.A stock PLN 43.61, price PLN 19.00, upside +129.5%, quality 56 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range 5.81 PLN – 31.28 PLN · fair‑value band 27.00 PLN – 55.33 PLN · the 19.00 PLN price screens below the 43.61 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow Biogened in your weekly email
Every Wednesday you see whether Biogened is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Biogened S.A. produces and sells cosmetics and toiletries in Poland. The company offers dermo-cosmetics under the Dermedic brand, as well as thermal water. It also exports its products. The company was incorporated in 2007 and is headquartered in Lódz, Poland.
Stock analysis
Biogened S.A (BGD) currently trades at 19.00 PLN, while our model-based Fair Value estimate is 43.61 PLN, implying the stock looks roughly 56% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 44.80 PLN per share, and 20 of the 26 models we run sit above the 19.00 PLN price.
Bear case: the Dividend Discount group reads lowest at 7.47 PLN, and 6 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 27.00 PLN (bear) to 55.33 PLN (bull), the price of 19.00 PLN sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Biogened S.A reported revenue of 113M PLN in FY2025 versus 79.6M PLN in FY2022, a compound +12.4%/yr. Reported net income was 4.9M PLN in FY2025, compounding +13.5%/yr from FY2022.
Key figures
Market cap 46.7M PLN (≈ $12.0M) Micro · P/E ratio 9.7 · P/S ratio 0.42 · EPS (TTM) 1.95 PLN · Dividend yield 2.6% · Net margin 4.7% · Return on equity 11.2% · Return on assets (EBIT) 10.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).
What moves the price
The share trades about 21% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 130%, BGD screens cheaper than that median.
Fair Value models
Bear27.00 PLNFair Value 43.61 PLNBull55.33 PLN
Price 19.00 PLN · Upside +129.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1.65 PLN per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.82/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+2.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+7.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+5.2%
Dividend (yield on the price)2.6%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 7%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−0.8%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Poland: IMF forecast 3.1% a year to 2030, 4.6% from 2016 to 2025) that is about −3.9% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 552 stocks
Beats the industry median on 11/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score56 · Above median
Fair Value upside+129.5% · Top 25%
Profitability
Return on equity (12 months)11.2% · Above median
Return on assets5.7% · Above median
Net margin (12 months)4.7% · Below median
Operating margin (12 months)8.2% · Below median
Growth and dividend
Revenue growth (quarter YoY)5.3% · Above median
Dividend yield (12 months)2.6% · Above median
Balance sheet
Debt / equity0.32× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Biogened S.A Fair Value". https://www.fairvalue-calculator.com/stock/BGD
Frequently asked questions
Is Biogened S.A (BGD) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 43.61 PLN versus a price of 19.00 PLN, about +130% upside (undervalued).
What is the fair value of BGD?
Our model-based fair value for Biogened S.A is 43.61 PLN (as of Nov 4, 2026), built from audited fundamentals. The current price: 19.00 PLN.
What is the quality score of BGD?
Biogened S.A has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biogened S.A (BGD)?
Our model-based price target is the fair value of 43.61 PLN (as of Nov 4, 2026) from 26 valuation models. Cautious scenario 27.00 PLN, optimistic scenario 55.33 PLN. It is a calculation from audited fundamentals, not an analyst target.
What is the Biogened S.A stock forecast for 2026?
Our models put fair value at 43.61 PLN, about +130% upside versus a price of 19.00 PLN (undervalued). Cautious scenario 27.00 PLN, optimistic scenario 55.33 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Biogened S.A (BGD)?
Biogened S.A reported trailing-twelve-month revenue of about 110M PLN (latest available figure, as of Nov 4, 2026).
Does Biogened S.A pay a dividend?
Biogened S.A currently shows a dividend yield of 2.63% relative to its recent price (as of Nov 4, 2026).
What growth is priced into Biogened S.A (BGD)?
For today's price to be fair in a discounted-cash-flow model, Biogened S.A would have to grow free cash flow by -0.8 % per year for five years (discount rate 9.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +12.4 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of BGD use?
Our models discount Biogened S.A at 9.3 %: a base by market capitalisation (nano), damped by beta 0.03, country premium for Poland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Biogened S.A that is -0.8 % per year a year over ten years, using the same discount rate (9.3 %) and the same formula as our fair value.
How much growth has Biogened S.A (BGD) delivered so far?
Over the past 3 years revenue at Biogened S.A grew +12.4 % a year. The price currently implies -0.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Biogened S.A (BGD) growing?
The median revenue growth in the sector is +6.4 % a year. That is the yardstick for the growth priced into Biogened S.A (-0.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Biogened S.A (BGD)?
The free-cash-flow yield on the price is 10.98 %: that much free cash flow Biogened S.A produces per unit of market value. When it exceeds the discount rate of our models (9.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Biogened S.A (BGD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biogened S.A it is 43.61 PLN per share (as of Nov 4, 2026), against a price of 19.00 PLN. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Biogened S.A stock overvalued or undervalued in 2026?
As of Nov 4, 2026, BGD trades below its calculated fair value: price 19.00 PLN, fair value 43.61 PLN, a gap of about +130% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BGD?
No. The price is what the market pays today (19.00 PLN); the fair value is what the company's own numbers justify (43.61 PLN). For Biogened S.A the two are 24.61 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Biogened S.A worth?
The market values Biogened S.A at about 46.7M PLN (market capitalisation, as of Nov 4, 2026). Per share that is 19.00 PLN; our models calculate a fair value of 43.61 PLN per share.
What do the bullish and bearish scenarios say about BGD?
Our models span a range for Biogened S.A: cautious scenario 27.00 PLN, base 43.61 PLN, optimistic 55.33 PLN per share (as of Nov 4, 2026, price 19.00 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BGD?
Biogened S.A trades at a price-to-earnings ratio of 9.7 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 43.61 PLN is built from several models across several years. Other multiples: P/B 1.0, P/S 0.4, EV/EBITDA 4.2.
How solid is the balance sheet of Biogened S.A (BGD)?
Balance-sheet figures for Biogened S.A (as of Nov 4, 2026): return on equity 11.2%, debt of 0.32 per unit of equity. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is BGD from its 52-week high?
Biogened S.A trades at 19.00 PLN, about 21% below its 52-week high of 24.14 PLN and 12% above the low of 16.93 PLN (as of Nov 3, 2026). Distance from the high says nothing about value: that is what the fair value of 43.61 PLN is for.
Which stocks are comparable to Biogened S.A?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biogened S.A stock attractive at the current price?
The data as of Nov 4, 2026: price 19.00 PLN, calculated fair value 43.61 PLN (+130%), Quality Score 56/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BGD calculated?
We run Biogened S.A through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 43.61 PLN, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0% above its aggregate fair value. Biogened S.A currently trades 56% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biogened S.A (BGD)?
The closing price on Nov 3, 2026 was 19.00 PLN. Our model-based fair value is 43.61 PLN, about +130% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biogened S.A right now?
The price is below even our cautious bear case (27.00 PLN). The market is more pessimistic than our downside scenario. Solid quality (56/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (27.00 PLN to 55.33 PLN) leaves room in how you read the outcome.
Key figures of Biogened S.A
How large is the market capitalisation of Biogened S.A (BGD)?
The market capitalisation of Biogened S.A is 46.7M PLN (≈ $12.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Biogened S.A (BGD)?
The price-to-sales ratio of Biogened S.A is 0.42 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Biogened S.A (BGD)?
Earnings per share at Biogened S.A are 1.95 PLN (price ÷ EPS = P/E 9.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Biogened S.A (BGD)?
The dividend yield of Biogened S.A is 2.6% (payout 25.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Biogened S.A (BGD)?
The net margin of Biogened S.A is 4.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biogened S.A (BGD)?
The return on equity (ROE) of Biogened S.A is 11.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biogened S.A (BGD)?
On an EBIT basis the return on assets of Biogened S.A is 10.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biogened S.A (BGD)?
The operating margin of Biogened S.A is 8.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biogened S.A (BGD)?
Revenue at Biogened S.A is growing +5.3% versus a year earlier (3y avg +12.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Biogened S.A (BGD)?
Earnings per share at Biogened S.A are growing −4.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Biogened S.A (BGD) carry?
The net debt of Biogened S.A is 14.7M PLN (fiscal year 2025, ≈ 2.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Biogened S.A in the live analysis
One click puts Biogened S.A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
